Tetravil is an immunocytokine, composed of the F8 antibody that recognizes the alternatively spliced EDA domain of fibronectin coupled with the immunoregulatory cytokine interleukin 4 (IL-4). The localization and retention of IL-4 allows an increased therapeutic index of the cytokine specifically at the sites of disease.

Tetravil shows unprecedented therapeutic activity in various models of rheumatoid arthritis, psoriasis, experimental autoimmune encephalomyelitis and endometriosis.
Tetravil is the first immunocytokine in Philogen's pipeline that is showing activity in both oncology and autoimmune disease indications.


Kawalkowska et al. (2016) Eur. J. Immunol. 46:1246-57;
Quattrone et al. (2015) Reprod. Science 22:1143-1152;
Hemmerle et al. (2015) J. Dermatology 76:96-103;
Hemmerle and Neri (2014) Int. J. Cancer 134:467-77;
Hemmerle et al. (2014) EULAR, Paris;
Hemmerle et al. (2014) Proc. Natl. Acad. Sci. USA 111:12008-12.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.

I Accept Cookie Policy